Skip to main content
. 2021 Oct 12;49(10):03000605211013199. doi: 10.1177/03000605211013199

Table 4.

Relationships between CDK14 and the clinical characteristics of patients with non-small cell lung cancer.

Variables Strong CDK14 staining (n = 129) Weak CDK14 staining (n = 64) P
Age, years 53.27 ± 11.93 52.46 ± 10.82 0.648
BMI, kg/m2 22.85 ± 3.03 22.54 ± 3.02 0.509
Sex, male:female (%) 78 (60.47):51 (39.53) 41 (64.06):23 (35.94) 0.600
Current smoker, n (%) 69 (53.49) 38 (59.38) 0.401
TNM stage, n (%) <0.001
 I–II 48 (37.21) 41 (64.06)
 III–IV 81 (62.79) 23 (35.94)
Pathological type, n (%) 0.018
 Squamous cell carcinoma 78 (60.47) 28 (43.75)
 Adenocarcinoma 51 (39.53) 36 (56.25)
 Pleural invasion, n (%) 79 (76.70) 24 (37.50) <0.001
 Lymph node metastasis, n (%) 97 (75.19) 31 (48.44) <0.001
 5-year survival, n (%) 9 (6.98) 11 (17.19) 0.027

CDK14, cyclin-dependent kinase 14; BMI, body mass index.